Loading clinical trials...

Special Investigation in Patients With Crohn's Disease (All Patients Investigation) | Clinical Trials | Clareo Health

COMPLETED

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Special Investigation (All Cases Investigation in Patients With Crohn's Disease)

NCT01298648•AbbVie (prior sponsor, Abbott)

Summary

This study will be conducted to assess adverse drug reactions, incidence of adverse events, and factors that may affect the safety and effectiveness of Humira for the treatment of Crohn's disease.

Eligibility

Age

16 - 99 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•All patients with moderate or severe active Crohn's disease who are not responding well to conventional therapy and receive Humira will be enrolled in the survey

Exclusion Criteria

•Contraindications according to the Package Insert
•Patients who have serious infections
•Patients who have tuberculosis
•Patients with a history of hypersensitivity to any ingredient of Humira
•Patients who have demyelinating disease or with a history of demyelinating disease
•Patients who have congestive cardiac failure

Locations (1131)

Site Reference ID/Investigator# 60378

Abiko, Japan

Site Reference ID/Investigator# 48682

Aichi, Japan

Site Reference ID/Investigator# 48693

Aichi, Japan

Site Reference ID/Investigator# 49011

Aichi, Japan

Site Reference ID/Investigator# 49013

Aichi, Japan

Site Reference ID/Investigator# 49015

Aichi, Japan

Site Reference ID/Investigator# 49016

Aichi, Japan

Site Reference ID/Investigator# 49019

Aichi, Japan

Site Reference ID/Investigator# 55615

Aichi, Japan

Site Reference ID/Investigator# 55616

Aichi, Japan

Key Dates

Start Date

November 1, 2010

Primary Completion Date

February 1, 2013

Completion Date

February 1, 2013

Last Updated

July 2, 2018

Enrollment

1,716

ACTUAL participants

Conditions

Crohn's Disease

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883

Inflammatory Bowel DiseasesCrohn's Disease

View study

RECRUITINGPHASE3

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931

Crohn's Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 2, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Special Investigation in Patients With Crohn's Disease (All Patients Investigation)

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease

Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas w/ Crohn's Disease